{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 55,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 46,
  "notes": "Waterfall plot shows best change in target lesion size; includes CA-125 response markers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/41",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Waterfall plot of best change in target lesion size by cancer type (EC, OC, BC, CCA)",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0c5c811-29db-4224-970e-3a74f68a214f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.33,
        "x": 0.63,
        "y": 0.25
      },
      "kind": "list",
      "text": "B7H4 target expression, efficacy, toxicity profile, and ongoing Phase II plans",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b2ae6eb-ab1c-4f11-958f-cae9b099b337",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "All doses are IV Q3W. Response based on RECIST v1.1... Abstract 6060 presented at the European Society of Medical Oncology 2024.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9c6c1ef-c397-4ada-8e58-2313b8f0db93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "AZD8205 – promising efficacy in heavily pre-treated patients with ovarian, breast and endometrial cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2041ab16-8866-4219-8e4a-cb096c2569e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "d33edad5-7fe2-48af-9a11-2a575edca3b4",
      "evidence": "chart/waterfall: Waterfall plot of best change in target lesion size by cancer type (EC, OC, BC, CCA)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}